[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Corcept Therapeutics (CORT)

Corcept Therapeutics (CORT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 9,684,223
  • Shares Outstanding, K 107,352
  • Annual Sales, $ 761,410 K
  • Annual Income, $ 99,650 K
  • EBIT $ -8 M
  • EBITDA $ -11 M
  • 60-Month Beta 0.47
  • Price/Sales 12.47
  • Price/Cash Flow 99.93
  • Price/Book 15.18

Options Overview Details

View History
  • Implied Volatility 58.34% (+0.12%)
  • Historical Volatility 39.89%
  • IV Percentile 63%
  • IV Rank 21.15%
  • IV High 138.94% on 12/15/25
  • IV Low 36.71% on 08/28/25
  • Expected Move (DTE 13) 2.55 (2.83%)
  • Put/Call Vol Ratio 0.04
  • Today's Volume 316
  • Volume Avg (30-Day) 776
  • Put/Call OI Ratio 0.27
  • Today's Open Interest 26,709
  • Open Int (30-Day) 27,016
  • Expected Range 87.66 to 92.76

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.04
  • Number of Estimates 3
  • High Estimate $0.02
  • Low Estimate $-0.09
  • Prior Year $0.29
  • Growth Rate Est. (year over year) -113.79%

Price Performance

See More
Period Period Low Period High Performance
1-Month
70.07 +28.74%
on 06/03/26
91.00 -0.87%
on 07/01/26
+19.01 (+26.70%)
since 06/02/26
3-Month
40.36 +123.51%
on 04/07/26
91.00 -0.87%
on 07/01/26
+47.72 (+112.31%)
since 04/02/26
52-Week
28.66 +214.76%
on 02/19/26
91.00 -0.87%
on 07/01/26
+18.87 (+26.45%)
since 07/02/25

Most Recent Stories

More News
3 High-Flying Stocks We Steer Clear Of

3 High-Flying Stocks We Steer Clear Of

CORT : 90.21 (+1.96%)
SEI : 67.19 (-8.49%)
DNUT : 3.51 (-5.65%)
Kuehn Law Encourages Investors of Corcept Therapeutics Incorporated to Contact Law Firm

NEW YORK , June 25, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Corcept Therapeutics Incorporated (NASDAQ:...

CORT : 90.21 (+1.96%)
3 Unpopular Stocks We Steer Clear Of

3 Unpopular Stocks We Steer Clear Of

CORT : 90.21 (+1.96%)
ASYS : 18.80 (-8.29%)
AAL : 17.92 (-1.27%)
Corcept Resubmits New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic...

CORT : 90.21 (+1.96%)
Corcept Presents New Data at ADA: Improved Outcomes in Patients Receiving a GLP-1 with Difficult-to-Control Type 2 Diabetes and Hypercortisolism Treated with Korlym®

New data from CATALYST and MOMENTUM trials presented at American Diabetes Association’s (ADA) 86 th Scientific Sessions In the CATALYST trial, patients with...

CORT : 90.21 (+1.96%)
1 of Wall Street’s Favorite Stocks with Exciting Potential and 2 We Question

1 of Wall Street’s Favorite Stocks with Exciting Potential and 2 We Question

CORT : 90.21 (+1.96%)
CENT : 43.95 (-0.90%)
G : 29.10 (+2.97%)
Corcept Presents New Data at ASCO 2026: Lifyorliâ„¢ Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including Those with Recent Taxane Exposure

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic...

CORT : 90.21 (+1.96%)
Corcept to Resubmit its New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic...

CORT : 90.21 (+1.96%)
S&P 500 and Nasdaq 100 Post New Record Highs on Chip Stock Strength

The S&P 500 Index ($SPX ) (SPY ) on Wednesday closed up +0.58%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed down -0.14%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +1.04%. June E-mini...

GOOGL : 359.91 (-0.36%)
AAPL : 308.63 (+4.84%)
INTU : 275.35 (+3.10%)
ADI : 377.16 (-3.04%)
F : 13.36 (-2.05%)
WIX : 49.35 (+0.96%)
AKAM : 113.17 (+0.32%)
TXN : 293.08 (-1.79%)
$IUXX : 29,329.21 (unch)
ASML : 1,769.32 (-4.00%)
ZNU26 : 109-175 (-0.03%)
MSFT : 390.49 (+1.62%)
Chip Stock Strength Lifts the Broader Market

The S&P 500 Index ($SPX ) (SPY ) today is up +0.18%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.58%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.60%. June E-mini S&P futures (ESM26...

ADI : 377.16 (-3.04%)
WIX : 49.35 (+0.96%)
AKAM : 113.17 (+0.32%)
TXN : 293.08 (-1.79%)
$IUXX : 29,329.21 (unch)
ZNU26 : 109-175 (-0.03%)
DT : 44.77 (-1.34%)
ESU26 : 7,557.00 (+0.38%)
QCOM : 176.25 (-3.12%)
$DOWI : 52,900.07 (+1.14%)
SPY : 744.78 (-0.13%)
DIA : 527.88 (+1.05%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

Relative Strength just crossed above 80%. The market has entered extreme overbought territory.

See More Share

Business Summary

Corcept is focused on the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncology disorders which are associated with the activity of the hormone cortisol, also known as the stress hormone. Corcept's only marketed drug, Korlym (mifepristone),...

See More

Key Turning Points

3rd Resistance Point 94.88
2nd Resistance Point 92.59
1st Resistance Point 91.40
Last Price 90.21
1st Support Level 87.92
2nd Support Level 85.63
3rd Support Level 84.44

See More

52-Week High 91.00
Last Price 90.21
Fibonacci 61.8% 67.19
Fibonacci 50% 59.83
Fibonacci 38.2% 52.47
52-Week Low 28.66

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.